# Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a 29.68% Upside Potential

- Link: https://www.directorstalkinterviews.com/tyra-biosciences-inc-tyra-stock-analysis-exploring-a-29-68-upside-potential/4121245622
- Published: 2026-03-20T11:24:46+00:00
- Author: Madison Wilson

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, is
making waves in the healthcare sector with its innovative approach to targeting 
fibroblast growth factor receptor (FGFR) biology. As a relatively recent entrant
to the biotechnology industry, Tyra Biosciences has carved out a niche with its 
precision medicine platform, SNÅP, which is designed to predict genetic alterations
for developing therapies aimed at oncology and genetically defined conditions.

With a market capitalization of $2.06 billion and a current stock price of $38.18,
Tyra has shown significant growth within its 52-week range of $7.06 to $38.18. Despite
the lack of profitability, as evidenced by its negative EPS of -2.01 and a forward
P/E ratio of -15.38, the company is capturing investor interest due to its promising
pipeline and strategic focus on FGFR-driven conditions.

Tyra Biosciences’ lead product candidate, FGFR3, is currently in clinical trials
for metastatic urothelial carcinoma and other solid tumors. Alongside this, the 
company is advancing TYRA-300 for skeletal conditions such as achondroplasia and
hypochondroplasia, TYRA-200 for intrahepatic cholangiocarcinoma, and TYRA-430 for
hepatocellular carcinoma. These developments highlight Tyra’s commitment to addressing
unmet medical needs through targeted therapies.

Investors should note that while the company does not yet report revenue growth 
or net income, it has garnered significant support from analysts. Tyra Biosciences
boasts an impressive 11 buy ratings, with zero hold or sell recommendations. The
average target price of $49.51 suggests a potential upside of 29.68%, a figure that
is likely to attract growth-oriented investors.

Technical indicators further underscore the stock’s momentum. The 50-day moving 
average stands at $32.03, and the 200-day moving average is $18.87, indicating a
strong upward trend. However, the Relative Strength Index (RSI) of 19.56 suggests
that the stock is currently oversold, which might present a buying opportunity for
investors looking to capitalize on potential price corrections.

Tyra’s free cash flow of -$54.55 million reflects the capital-intensive nature of
biotechnology ventures, especially those at the clinical stage. The absence of a
dividend yield and a payout ratio of 0.00% indicate that the company is reinvesting
its resources into research and development to fuel future growth.

For investors considering Tyra Biosciences, the key takeaway is the significant 
growth potential underscored by its innovative pipeline and robust analyst support.
While the company is yet to achieve profitability, its strategic focus on precision
medicine and targeted therapies positions it as a compelling prospect within the
biotechnology sector. As always, potential investors should weigh the inherent risks
associated with clinical-stage biotech companies against the promising upside potential.

Share on: